Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: GlobeNewswire
- Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19 - In a mouse H1N1 influenza model, delayed (up to 4 days) verdinexor treatment: (A) significantly reduces influenza virus levels; (B) ameliorated lung injury; and (C) improved survival In a lipopolysaccharide (LPS)-induced sepsis model, selinexor (A) attenuated lung injury, (B) reduced serum cytokines levels, (C) reduced macrophage and polymorphonuclear (PMN) subpopulations in the peritoneal exudate and improved survival - XPO1 Inhibitors have Previously Demonstrated Preclinical Activity Against Numerous Respiratory Viruses (Inc
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]Yahoo! Finance
- What Recent Analyst Forecasts Mean for the Changing Story Behind Karyopharm Therapeutics [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/3/25 - Miss
KPTI
Sec Filings
- 11/24/25 - Form 424B3
- 11/24/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- KPTI's page on the SEC website